These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36711952)

  • 21. Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.
    Ilahibaks NF; Kluiver TA; de Jong OG; de Jager SCA; Schiffelers RM; Vader P; Peng WC; Lei Z; Sluijter JPG
    J Extracell Vesicles; 2024 Jan; 13(1):e12389. PubMed ID: 38191764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
    Lotta LA; Stewart ID; Sharp SJ; Day FR; Burgess S; Luan J; Bowker N; Cai L; Li C; Wittemans LBL; Kerrison ND; Khaw KT; McCarthy MI; O'Rahilly S; Scott RA; Savage DB; Perry JRB; Langenberg C; Wareham NJ
    JAMA Cardiol; 2018 Oct; 3(10):957-966. PubMed ID: 30326043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the possible existence of a liver LDL-ostat, and its malfunctioning in familial hypercholesterolemia.
    Teixeira da Costa LF
    Med Hypotheses; 2021 Feb; 147():110500. PubMed ID: 33515861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study.
    Smith ML; Bull CJ; Holmes MV; Davey Smith G; Sanderson E; Anderson EL; Bell JA
    EBioMedicine; 2023 Apr; 90():104503. PubMed ID: 36870196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polygenic Hyperlipidemias and Coronary Artery Disease Risk.
    Ripatti P; Rämö JT; Mars NJ; Fu Y; Lin J; Söderlund S; Benner C; Surakka I; Kiiskinen T; Havulinna AS; Palta P; Freimer NB; Widén E; Salomaa V; Tukiainen T; Pirinen M; Palotie A; Taskinen MR; Ripatti S;
    Circ Genom Precis Med; 2020 Apr; 13(2):e002725. PubMed ID: 32154731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-Brief Report.
    Gratton J; Humphries SE; Futema M
    Arterioscler Thromb Vasc Biol; 2023 Sep; 43(9):1737-1742. PubMed ID: 37409534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular BChE as a therapeutic target to ameliorate hypercholesterolemia through PRMT5 selective degradation to restore LDL receptor transcription.
    Wang D; Tan KS; Zeng W; Li S; Wang Y; Xu F; Tan W
    Life Sci; 2022 Mar; 293():120336. PubMed ID: 35065166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.
    Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Keep recycling going: New approaches to reduce LDL-C.
    Klein-Szanto AJP; Bassi DE
    Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL-C and LPA genetic scores.
    Schwaninger G; Forer L; Ebenbichler C; Dieplinger H; Kronenberg F; Zschocke J; Witsch-Baumgartner M
    Clin Genet; 2023 Sep; 104(3):334-343. PubMed ID: 37417318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids.
    Handelman SK; Puentes YM; Kuppa A; Chen Y; Du X; Feitosa MF; Palmer ND; Speliotes EK
    Hepatol Commun; 2022 Nov; 6(11):3120-3131. PubMed ID: 36098472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and analysis of individuals who deviate from their genetically-predicted phenotype.
    Hawkes G; Yengo L; Vedantam S; Marouli E; Beaumont RN; ; Tyrrell J; Weedon MN; Hirschhorn J; Frayling TM; Wood AR
    PLoS Genet; 2023 Sep; 19(9):e1010934. PubMed ID: 37733769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure.
    Clarke SL; Tcheandjieu C; Hilliard AT; Lee KM; Lynch J; Chang KM; Miller D; Knowles JW; O'Donnell C; Tsao PS; Rader DJ; Wilson PW; Sun YV; Gaziano JM; Assimes TL;
    Circ Genom Precis Med; 2022 Apr; 15(2):e003501. PubMed ID: 35143253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease.
    Linsel-Nitschke P; Heeren J; Aherrahrou Z; Bruse P; Gieger C; Illig T; Prokisch H; Heim K; Doering A; Peters A; Meitinger T; Wichmann HE; Hinney A; Reinehr T; Roth C; Ortlepp JR; Soufi M; Sattler AM; Schaefer J; Stark K; Hengstenberg C; Schaefer A; Schreiber S; Kronenberg F; Samani NJ; Schunkert H; Erdmann J
    Atherosclerosis; 2010 Jan; 208(1):183-9. PubMed ID: 19660754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
    Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
    Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-Specific Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells as a Model to Study Autosomal Recessive Hypercholesterolemia.
    Nikasa P; Tricot T; Mahdieh N; Baharvand H; Totonchi M; Hejazi MS; Verfaillie CM
    Stem Cells Dev; 2021 Jul; 30(14):714-724. PubMed ID: 33938231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.
    O'Hare EA; Wang X; Montasser ME; Chang YP; Mitchell BD; Zaghloul NA
    J Lipid Res; 2014 Nov; 55(11):2242-53. PubMed ID: 25201834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic and Genetic Characterization of Lower LDL Cholesterol and Increased Type 2 Diabetes Risk in the UK Biobank.
    Klimentidis YC; Arora A; Newell M; Zhou J; Ordovas JM; Renquist BJ; Wood AC
    Diabetes; 2020 Oct; 69(10):2194-2205. PubMed ID: 32493714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.